Ignite Creation Date:
2025-12-24 @ 4:40 PM
Ignite Modification Date:
2026-02-01 @ 10:28 AM
Study NCT ID:
NCT02562066
Status:
COMPLETED
Last Update Posted:
2021-04-02
First Post:
2015-09-24
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Amifampridine Phosphate for the Treatment of Congenital Myasthenic Syndromes
Sponsor:
Catalyst Pharmaceuticals, Inc.
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Myasthenic Syndromes, Congenital | View |
Keywords: